Please login to the form below

Not currently logged in

KeyNote-158 trial

This page shows the latest KeyNote-158 trial news and features for those working in and with pharma, biotech and healthcare.

More good news, and some bad, for Merck’s Keytruda

More good news, and some bad, for Merck’s Keytruda

The application is for accelerated approval based on the results of the KEYNOTE-158 trial, which showed that Keytruda, given as a monotherapy to SCLC patients whose cancer had progressed despite ... Liver failure. On the downside, Merck also revealed

Latest news

More from news
Approximately 0 fully matching, plus 1 partially matching documents found.

COVID-19 Updates and Daily News

Featured jobs


Add my company
Porterhouse Medical Group

The Porterhouse Medical Group provides powerful, insight-driven, scientific and medical communication services to the pharmaceutical industry across the globe, with...

Latest intelligence

Kulveer Singh
Surviving cancer: a new era for patients
Now more than ever, a shift in perspective is needed...
Crisis? No problem!
Issues planning & management for pharma spokespeople, by Andrew Smith...
Are patient recruitment and retention rates rising or falling?
First up, the good news. Over the past seven years, clinical trial recruitment rates have been on the rise....